康辰药业(603590)9月1日晚间发布股票交易异动公告称，经自查，并书面征询控股股东、实控人，截至 目前，除公司已披露事项外，不存在应披露而未披露的重大信息。 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-050 北京康辰药业股份有限公司 关于股票交易异常波动的公告 二、 公司关注并核实的相关情况 （一）生产经营情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 北京康辰药业股份有限公司（以下简称"公司"）股票于 2025 年 8 月 29 日、9 月 1 日连续 2 个交易日收盘价格涨幅偏离值累计超过 20%，属于股票交易 异常波动情形。 经公司自查，并书面征询控股股东、实际控制人，截至本公告披露日， 除本公司已披露事项外，不存在应披露而未披露的重大信息。 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、 股票交易异常波动的具体情况 公司股票交易于 2025 年 8 月 29 日、9 月 1 日连续 2 个交易日收盘价格涨幅 偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票 交易异常波动情形。 经公司自查，公司目前生产经营活动一切正常，日常经营情况未发生重大变 化。 （二）重大事项情况 经公司自查，并向 ...

Market Performance - The biopharmaceutical sector increased by 2.93% on September 1, with Zhixiang Jintai leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Biopharmaceutical Sector - Zhixiang Quantai (688443) closed at 37.02, up 12.11% with a trading volume of 162,600 shares and a transaction value of 591 million [1] - Yiqiao Shenzhou (301047) closed at 82.09, up 10.65% with a trading volume of 56,000 shares and a transaction value of 450 million [1] - Kangchen Pharmaceutical (603590) closed at 61.79, up 10.01% with a trading volume of 78,600 shares and a transaction value of 480 million [1] - Changchun High-tech (000661) closed at 113.37, up 10.00% with a trading volume of 211,700 shares and a transaction value of 2.357 billion [1] - Kangtai Biological (300601) closed at 20.49, up 9.51% with a trading volume of 546,700 shares and a transaction value of 1.08 billion [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 773 million from institutional investors, while retail investors experienced a net outflow of 328 million [2][3] - Major stocks like Changchun High-tech and Kangtai Biological had significant net inflows from institutional investors, indicating strong interest [3]

Group 1 - The innovative drug sector is experiencing active trading, with companies like Maiwei Bio reaching a 20% limit up and others like Yipin Hong and Zhixiang Jintai seeing over 10% gains [1] - The innovative drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [1] - The adjustment of the medical insurance catalog will include commercial insurance for innovative drugs for the first time, indicating a positive trend for the sector [1] Group 2 - According to CICC, domestic engineer dividends, abundant clinical resources, and supportive policies are contributing to the transition of domestic innovative drugs from following to FIC and BIC innovation [1] - The innovative drug industry is entering a 2.0 era, having completed qualitative improvements, with strong pipeline data and ongoing large BD transactions [1] - The upcoming ESMO conference in mid-October is expected to bring new investment opportunities for the sector based on clinical data releases and BD activities [1] Group 3 - Since 2025, policies related to commercial health insurance have been continuously promoted, which is expected to accelerate payment reform in the medical system and support domestic innovation [2] - Recent policies on childcare subsidies are anticipated to alleviate long-term population pressures and stimulate consumption related to infants and young children [2] - With the increase in fiscal policies, domestic medical equipment-related stocks are also gaining market attention [2]

Group 1 - Kangchen Pharmaceutical and Puris reached the daily limit increase, while Duri Pharmaceutical rose over 10% [1] - Huahai Pharmaceutical, Haoyuan Pharmaceutical, Jimin Health, Warner Pharmaceuticals, and Medisyn also experienced gains [1]

Group 1 - The company reported a revenue of 461 million yuan for the first half of 2025, representing a year-on-year growth of 13.79% [1] - The net profit attributable to shareholders reached 91 million yuan, with a year-on-year increase of 14.95% [1] - The net profit after deducting non-recurring items was 96 million yuan, showing a year-on-year growth of 29.21% [1] Group 2 - The company’s R&D system is maturing, with the first patient enrolled in the KC1086 trial, and over 300 patients enrolled in the KC1036 trial, achieving an ORR of 26.1% for ESCC [2] - The sales expense ratio decreased to 44.35%, down by 3.49 percentage points, while the management expense ratio was 14.47%, up by 0.51 percentage points [2] - The company is expanding its self-operated transformation to 19 provinces, benefiting from an efficient digital promotion model [2] Group 3 - The company plans to invest 150 million yuan in Yourui Cayman’s E-round financing, increasing its shareholding to 7.98% [3] - Yourui Cayman’s key pipeline, ensifentrine, received FDA approval for COPD treatment in 2024, with plans to submit an NDA in the second half of 2025 [3] - The company maintains a "recommended" rating, forecasting net profits of 133 million, 177 million, and 214 million yuan for 2025-2027 [3]

Core Points - The company has announced the first unlock date and listing of its restricted stock incentive plan for 2023, with 190,000 shares set to be listed on September 4, 2025 [1][7] - The stock incentive plan has undergone multiple meetings and approvals, with independent opinions from directors and verification from the supervisory board [2][4] - The first unlock period for the reserved stock is set to expire on September 3, 2025, with specific performance conditions that must be met for the unlock to occur [5][6] Implementation of the Incentive Plan - The incentive plan has been approved through three meetings, with relevant proposals and independent opinions documented [2][4] - The company completed the registration of the first grant of restricted stock on September 21, 2023, awarding 2.49 million shares to 21 incentive recipients [2][3] - The reserved stock grant was registered on September 4, 2024, with 530,000 shares awarded to 13 recipients [3][4] Unlock Conditions and Performance Metrics - The first unlock conditions for the reserved stock require the company to achieve a net profit growth rate of at least 30% for 2024, based on 2022 figures [5][6] - Individual performance assessments will determine the unlock ratio for each recipient, with a total of 11 recipients meeting the conditions for unlock [6][7] - The total number of shares eligible for unlock is 190,000, representing 0.12% of the company's total share capital [7][8] Changes in Share Capital Structure - Following the unlock, the number of restricted shares will decrease from 2,119,000 to 1,929,000, while the number of unrestricted shares will increase from 157,237,477 to 157,427,477 [8] - The total share capital remains unchanged at 159,356,477 shares [8] Legal Compliance - The company has confirmed that all procedures related to the unlock of the reserved stock comply with relevant regulations and internal policies [8][9]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-049 北京康辰药业股份有限公司 一、公司 2023 年限制性股票激励计划（简称 "本激励计划"）实施情况 （一）股权激励计划已履行的程序 1、2023 年 7 月 31 日，公司召开第四届董事会第四次会议、第四届监事会第 三次会议，审议通过《关于公司<2023 年限制性股票激励计划（草案）>及其摘要 的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》等议 案。公司独立董事就本激励计划相关议案发表了独立意见。公司监事会对本激励 计划相关事项进行核实并出具了相关核查意见。 关于公司 2023 年限制性股票激励计划预留授予 第一个限售期解除限售暨上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 190,000股。 本次股票上市流通总数为190,000股。 本次股票上市流通日期为2025 年 9 月 4 日。 2、2023 年 8 月 1 日至 20 ...

北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划首次授予部分 第二个解除限售期、预留授予部分第一个解除限售期 解除限售条件成就及回购注销事项的 法律意见书 国枫律证字[2023]AN138-7 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel） 010-88004488/66090088 传真（Fax): 010-66090016 北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划首次授予部分 法律意见书 国枫律证字[2023] AN138-7号 致:北京康辰药业股份有限公司 根据本所与康辰药业签署的《律师服务协议书》,本所接受康辰药业的委托,担 任康辰药业本次股权激励计划的特聘专项法律顾问,并已出具了《北京国枫律师事 务所关于北京康辰药业股份有限公司 2023 年限制性股票激励计划(草案)的法律意 见书》《北京国枫律师事务所关于北京康辰药业股份有限公司 2023 年限制性股票激 励计划首次授予事项的法律意见书》《北京国 ...

Market Overview - The biopharmaceutical sector increased by 0.85% on August 29, with Kangchen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Biopharmaceutical Sector - Kangchen Pharmaceutical (603590) closed at 56.17, up 10.01% with a trading volume of 67,100 shares and a transaction value of 366 million [1] - Rongchang Biopharmaceutical (688331) closed at 90.88, up 8.35% with a trading volume of 166,100 shares [1] - Sanofi Biopharmaceutical (688336) closed at 52.60, up 8.01% with a trading volume of 89,900 shares [1] - Baipusais (301080) closed at 58.61, up 7.34% with a trading volume of 42,800 shares [1] - Wanzhe Co. (000534) closed at 17.70, up 6.31% with a trading volume of 382,900 shares [1] Top Losers in Biopharmaceutical Sector - Tibet Pharmaceutical (600211) closed at 47.16, down 3.42% with a trading volume of 193,800 shares and a transaction value of 912 million [2] - Wendi Pharmaceutical (688488) closed at 17.36, down 2.36% with a trading volume of 126,200 shares [2] - Chengda Biopharmaceutical (688739) closed at 27.90, down 2.35% with a trading volume of 50,700 shares [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 506 million from institutional investors, while retail investors saw a net inflow of 402 million [2] - The top stocks by net inflow from institutional investors included Rongchang Biopharmaceutical with a net inflow of 127 million [3] - Kangchen Pharmaceutical had a net inflow of 68 million from institutional investors, but also saw outflows from retail investors [3]